Glaxo Provides 50m Pandemic Vaccines
In order to support governments and health authorities around the world to respond to the outbreak of global flu, British pharmaceutical giant GlaxoSmithKline has offered 50 million doses of pandemic vaccine to the World Health Organization (WHO).
The company took this step in response to an appeal made by the UN and WHO to drug makers to save some of their pandemic vaccines for poor nations. The offer was made during a meeting between the UN officials, vaccine makers and other health experts. In addition, Glaxo will reduce its pandemic vaccine prices for developing nations.
Glaxo has received orders from several countries to stockpile pandemic flu vaccine. But it will start making the vaccine as soon as it gets the vaccine’s key ingredient, a “seed stock” based on the virus.
Related Insight
Suppliers Directory
Congenix - Contract Research Services
Congenix is a regional contract research organization offering its clients a full range of services, covering the strategic development of clinical programs for all phases (I-IV) in the Russian Federation and Commonwealth of Independent States. Our project managers and monitors expertise at the local level will guide you through the logistics of identifying best sites and investigators for your studies, understanding local regulations and offer direct contact with key opinion leaders on your clinical development plan. In order to demonstrate our expertise and the real potential of our region, we offer protocol specific assessments in Russia and neighboring countries to sponsors at no cost.
Suppliers
SHL Group - Designer, Developer & Supplier of Auto Injectors & Pen Injectors
SHL (Scandinavian Health Ltd.) is the world's largest privately-owned designer, developer and supplier of advanced drug delivery devices.
Regulatory Affairs > Suppliers
Cresset - Molecular Field Technology
Cresset develops and sells an innovative range of chemistry tools for molecular modellers, medicinal chemists and safety, in-licensing and IP specialists within the life science industry.
Suppliers
Dr. Paul Lohmann® - Mineral Salts
Dr. Paul Lohmann GmbH KG is the world’s leading provider of high-purity mineral salts to the pharmaceutical, nutrition and dietary supplement industries. Our 125 years of manufacturing experience – combined with innovation and flexibility – enables us to respond rapidly to your changing needs. We provide customers with the broadest available portfolio of mineral salts, with more than 350 products and over 1,000 qualities, designed to provide optimum performance across a wide range of applications.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Delivery Intelligence
Life Sciences Product List 2012
Published by Randox
White Papers
Comprehensive Feasibility Assessments in Eastern Europe - Luxury or Necessity?
Published by Centrical Global Limited
White Papers
An Interview with Paul Gerteis
Published by Gerteis
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.